Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Revenue from operations climbed 13% to Rs. 886.87 crore
Expands Davaindia network to 2,579 stores
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The company reported free cash flow of Rs. 2,590 Mn for FY26
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Subscribe To Our Newsletter & Stay Updated